Upstream Bio (UPB) shares saw an increase in after-hours trading on Friday following the company's presentation of ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

Type 2 CRSwNP is linked to worse health-related quality of life, with higher rates of smell loss and rhinorrhea emerging as ...

Thymic Stromal Lymphopoietin (TSLP) is a cytokine that is a key driver of the inflammatory response in major allergic and ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respirator ...

In patients with chronic rhinosinusitis with nasal polyps, factors including baseline antibiotic use and asthma impacted the ...

A new Canadian real-world study, ACTIONS (chAracterizing oral Corticosteroid use in patients with chronic rhInOsinusitis with ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

“Some biologics have been approved by the FDA and EMA for the add-on therapy for treatment of adults with CRSwNP.” Additionally, he said, CRSwNP has a negative impact on quality of life with ...

Most people with a condition known as chronic rhinosinusitis with nasal polyps (CRSwNP) are able to control their symptoms by using medicines that are sprayed into the nose or taken by mouth.

This approval expands the initial June 2019 FDA approval in CRSwNP for patients aged 18 years and older. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is ...

The approval in adolescent patients with CRSwNP was also supported by pharmacokinetic data from adult and pediatric patients aged 12 years and older with moderate to severe asthma and adult ...